A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors

Clinical Cancer Research

Volumn 12, Issue 16, 2006, Pages 4882-4887

  Fox, Elizabeth ^a   Maris, John M ^b   Widemann, Brigitte C ^a   Meek, Kysa ^d   Goodwin, Anne ^a   Goodspeed, Wendy ^a   Kromplewski, Marie ^b   Fouts, Molly E ^c   Medina, Diane ^d   Cho, Steve Y ^a   Cohn, Susan L ^c   Krivoshik, Andrew ^d   Hagey, Anne E ^d   Adamson, Peter C ^b   Balis, Frank M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c CHILDREN'S MEMORIAL HOSPITAL   (United States)

^d ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIEMETIC AGENT; ASPARTATE AMINOTRANSFERASE; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; PROTEIN INHIBITOR; TUBULIN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BONE MARROW SUPPRESSION; BRADYCARDIA; BRAIN TUMOR; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIZZINESS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CAPSULE; EPISTAXIS; FATIGUE; FEVER; HEADACHE; HUMAN; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTENSION; ILEUS; INSOMNIA; MOTOR NEUROPATHY; MYALGIA; NAUSEA; NEPHROBLASTOMA; NEUROBLASTOMA; NEUTROPENIA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BINDING; SARCOMA; SCHOOL CHILD; SENSORY NEUROPATHY; SIDE EFFECT; SOLID TUMOR; TACHYCARDIA; THROMBOCYTOPENIA; VOMITING; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; ADOLESCENT; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; SULFONAMIDES; TUBULIN MODULATORS;

EID: 33748372759     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0534     Document Type: Article

References (14)

1. Yoshimatsu K, Yamaguchi A, Yoshino H, et al. Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin. Cancer Res 1997;57:3208-13.
2. Galmarini C. ABT-751. Curr Opin Investig Drugs 2005;6:623-30.
3. Koyanagi N, Nagasu T, Fujita F, et al. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors. Cancer Res 1994;54:1702-6.
4. Owa T, Yokoi A, Yamazaki K, et al. Array-based structure and gene expression relationship study of antitumor sulfonamides including N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide and N-(3-chloro-7-indolyl)-1,4-benzenedisulfonamide. J Med Chem 2002;45:4913-22.
5. Yokoi A, Kuromitsu J, Kawai T, et al. Profiling novel sulfonamide antitumor agents with cell based phenotypic screens and array based gene expression analysis. Mol Cancer Ther 2002;1:275-86.
6. Segreti J, Polakowski JS, Dierks K, et al. Tumor selective vascular effects of the novel antimitotic compound ABT-751 in an in vivo rat regional hemodynamic study. Cancer Chemother Pharmacol 2004;54:273-81.
7. Hande K, Meek K, Lockhart AC, et al. Pharmacokinetics and safety of ABT-751 a novel microtubulin inhibitor administered daily × 7 days every 3 weeks. Proc Am Soc Clin Oncol 2003;22:#520.
8. Sprague E, Fleming GF, Cai Y, et al. Phase I study of 21 day continuous dosing of oral antimitotic agent ABT-751 a novel microtubulin inhibitor. Proc Am Soc Clin Oncol 2003;22:#518.
9. Kobayashi H, Hande K, Berlin J, et al. Phase I results of ABT-751 a novel microtubulin inhibitor administered daily × 7 every 3 weeks [abstract 2079]. Proc Am Soc Clin Oncol 2004;145:23.
10. Giles F, Cortes J, Thomas D, et al. Phase I study of ABT-751 a novel tubulin binding agent in patients with refractory hematological malignancies. Blood 2003;102:4735.
11. Gardner R, Broman M. The Purdue pegboard: normative data on 1334 school children. J Clin Psychol 1979;1:156-62.
12. Crom W, deGraff SSN, Synold T, et al. Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemia. J Pediatr 1994;125:642-9.
13. Hurwitz C, Relling MV, Weitman SD, et al. Phase I trail of paclitaxel in children with refractory solid tumors: a Pediatric Oncology Group Study. J Clin Oncol 1993;11:2324-9.
14. Blaney S, Seibel NL, O'Brien M, et al. Phase I trial of docetaxel administered as a 1 hour infusion in children with refractory solid tumors: a collaborative Pediatric Branch, NCI and Children's Cancer Group Trial. J Clin Oncol 1997;15:1538-43.